BEPRIDIL HYDROCHLORIDE

US Previously Marketed

First approved in 1990

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H34N2O.ClH.H2O
Molecular Weight	421.016
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.Cl.CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3

InChI

InChIKey=UEECHQPWQHYEDE-UHFFFAOYSA-N

InChI=1S/C24H34N2O.ClH.H2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22;;/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3;1H;1H2

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C24H34N2O
Molecular Weight	366.5396
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rxlist.com/vascor-drug.htm
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/bepridil.html | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075 | https://www.ncbi.nlm.nih.gov/pubmed/1280569

Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It has inhibitory effects on both the slow calcium and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. It is used to treat hypertension (high blood pressure), angina (chest pain), sustained atrial fibrillation and tachyarrhythmia. The most common side effects were upper gastrointestinal complaints (nausea, dyspepsia or GI distress), diarrhea, dizziness, asthenia and nervousness. Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride. In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants. Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride. Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Beta-secretase (BACE) 5 Target ID: CHEMBL2111390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218	Inhibitor 8504	6.0 µM [IC50]
Gamma-secretase 21 Target ID: CHEMBL2094135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20592218	Modulator 846
potassium sodium-activated channel subfamily T member 1 3 Target ID: 57582.0 Gene Symbol: KCNT1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16876206	Inhibitor 8504	1.0 µM [IC50]
Voltage and receptor operated calcium channels 3 Target ID: Voltage and receptor operated calcium channels Sources: http://www.rxlist.com/vascor-drug.htm	Blocker 555

Conditions

Condition	Modality	Highest Phase	Product
Chronic stable angina 10 Sources: http://www.rxlist.com/vascor-drug.htm	Primary	Approved 8583	BEPRICOR Approved Use Bepridil hydrochloride is indicated for the treatment of chronic stable angina (classic effort-associated angina).
Hypertension 575 Sources: https://www.drugs.com/mtm/bepridil.html	Primary	Approved 8583	BEPRICOR Approved Use Bepridil is used to treat hypertension (high blood pressure) and to treat angina (chest pain).
Atrial fibrillation 131 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075	Primary	Approved 8583	BEPRICOR Approved Use It is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina.
Tachyarrhythmia 17 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1075	Primary	Approved 8583	BEPRICOR Approved Use It is usually used to treat sustained atrial fibrillation, tachyarrhythmia (ventricular) and angina.

C_max

Value	Dose	Co-administered	Analyte	Population
806 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
4.87 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
38.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7650227	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		BEPRIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.3% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3875635			BEPRIDIL plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Weakness, Lightheadedness... AEs leading to discontinuation/dose reduction: Weakness (2 patients) Lightheadedness (1 patient) Syncopal attack (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 39-84 years Health Status: unhealthy Age Group: 39-84 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Electrocardiogram QTc interval prolonged... AEs leading to discontinuation/dose reduction: Electrocardiogram QTc interval prolonged (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	Disc. AE: Nausea, Diarrhea... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Diarrhea (1 patient) Anorexia (1 patient) Bigeminy (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (1 patient) Bradycardia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	Disc. AE: Ventricular tachycardia, Bradycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia (grade 5, 1 patient) Bradycardia (1 patient) Electrocardiogram QTc interval prolonged (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/

AEs

AE	Significance	Dose	Population
Lightheadedness	1 patient Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Syncopal attack	1 patient Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Weakness	2 patients Disc. AE	400 mg 1 times / day steady, oral Studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 34-77 years Health Status: unhealthy Age Group: 34-77 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Electrocardiogram QTc interval prolonged	1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 39-84 years Health Status: unhealthy Age Group: 39-84 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Anorexia	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Bigeminy	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Diarrhea	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Nausea	1 patient Disc. AE	300 mg 1 times / day steady, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/	unhealthy, 43-80 years Health Status: unhealthy Age Group: 43-80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3919556/
Bradycardia	1 patient Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Ventricular tachycardia	1 patient Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 63.5 years Health Status: unhealthy Age Group: 63.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Bradycardia	1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Electrocardiogram QTc interval prolonged	4 patients Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/
Ventricular tachycardia	grade 5, 1 patient Disc. AE	200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/	unhealthy, 64.6 years Health Status: unhealthy Age Group: 64.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19359813/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507 substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2E1 1060	CYP1A2 1197 P-gp 2052 BCRP 697

Drug as perpetrator

Target	Modality	Activity
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11344532/	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19702529/	yes
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/32906709/	yes

Drug as victim

Target	Modality	Activity
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28210973/	no
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19196847/	yes
P-gp 2052	substrate 4014 Sources: https://www.futuremedicine.com/doi/abs/10.1517/14622416.2.4.401	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY565364	https://www.001chemical.com/chem/64706-54-3
3B Scientific (Wuhan) Corp	3B2-0571	http://www.3bsc.com/index/pro_info.php?id=19927
abcr GmbH	AB542520	http://www.abcr.com/shop/en/AB542520
Achemo Scientific Limited	AC-11145	http://www.achemo.com/search/?Keyword=64706-54-3
AHH Chemical co.,ltd	API-1541	http://www.ahhchemical.com/product/API-1541.html
AK Scientific, Inc. (AKSCI)	K042	http://www.aksci.com/item_detail.php?cat=K042
Angel Pharmatech	AG121309	http://www.angelpharmatech.com/64706-54-3.html
BLD Pharm	BD116381	http://www.bldpharm.com/products/64706-54-3.html
ChemMol	30105085	http://www.chemmol.com/chemmol/30105085.html
ChemMol	99124623	http://www.chemmol.com/chemmol/99124623.html
Chemspace	CSSB00000047941	https://chem-space.com/CSSB00000047941
CSNpharm	CSN10416	https://www.csnpharm.com/products/bepridil.html
Debye Scientific	DB-054717	http://www.debyesci.com/cas_64706-54-3.html
Finetech	FT-0630749	http://www.finetechnology-ind.com/prod/detail/pub/64706-54-3.html
Glentham Life Sciences	GP4395	http://www.glentham.com/products/product/GP4395/
Lab Network	LN00330174	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00330174
Molcore	MC565364	https://www.molcore.com/product/64706-54-3
Smolecule	S520991	http://www.smolecule.com/products/s520991
Smolecule	S772535	https://www.smolecule.com/products/s772535
THE BioTek	bt-261730	https://www.thebiotek.com/product/inhibitors/bt-261730
THE BioTek	bt-311849	https://www.thebiotek.com/product/others/bt-311849
Vesino Industrial Co Ltd	VA10387	http://www.vsnchem.com/goto/product/23859/

PubMed

Title	Date	PubMed
Biliary drug lithiasis: dipyridamole gallstones.	1992 Nov 28	1360065
Cancer chemopreventive activities of S-3-1, a synthetic derivative of danshinone.	2001	11355772
Blocking effect of bepridil on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes.	2001 Apr	11388640
A quinolone alkaloid with antioxidant activity from the aleurone layer of anthocyanin-pigmented rice.	2001 Dec	11754619
New bis-catechols 5-lipoxygenase inhibitors.	2001 Feb	11249115
Axonal L-type Ca2+ channels and anoxic injury in rat CNS white matter.	2001 Feb	11160521
Stimulation of nitric oxide-cGMP pathway excites striatal cholinergic interneurons via protein kinase G activation.	2001 Feb 15	11160411
In vitro evaluation of the antioxidant activity and biomembrane interaction of the lazaroid U-74389G.	2001 Feb 9	11388688
The antioxidant activity of the essential oils of Artemisia afra, Artemisia abyssinica and Juniperus procera.	2001 Mar	11268106
Antioxidant activities of buckwheat hull extract toward various oxidative stress in vitro and in vivo.	2001 Mar	11256471
Relationship between effects of phenolic compounds on the generation of free radicals from lactoperoxidase-catalyzed oxidation of NAD(P)H or GSH and their DPPH scavenging ability.	2001 Mar	11253920
Traumatic axonal injury induces calcium influx modulated by tetrodotoxin-sensitive sodium channels.	2001 Mar 15	11245677
Radical scavenging activity against 1,1-diphenyl-2-picrylhydrazyl of ascorbic acid 2-glucoside (AA-2G) and 6-acyl-AA-2G.	2001 May	11383624
A novel series of thromboxane A2 synthetase inhibitors with free radical scavenging and anti-peroxidative activities.	2001 May	11383607
Effect of the antianginal drug bepridil on intracellular Ca2+ release and extracellular Ca2+ influx in human neutrophils.	2001 May	11379049
Synthesis and in vitro studies of pyrone derivatives as scavengers of active oxygen species.	2001 Nov	11765588
Sorbicillinol, a key intermediate of bisorbicillinoid biosynthesis in Trichoderma sp. USF-2690.	2001 Oct	11758920
Superoxide- and 1,1-diphenyl-2-picrylhydrazyl radical-scavenging activities of soyasaponin beta g related to gallic acid.	2001 Oct	11758904
Antagonistic effects of 24R,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 on L-type Ca2+ channels and Na+/Ca2+ exchange in enterocytes from Atlantic cod (Gadus morhua).	2002 Feb	11854099
Antioxidant capacities of ten edible North American plants.	2002 Feb	11807968
Interaction of digoxin with antihypertensive drugs via MDR1.	2002 Feb 15	11895100
Antioxidant effects of 1,5-anhydro-D-fructose, a new natural sugar, in vitro.	2002 Jan	11842320
Free radical scavenging properties of wheat extracts.	2002 Mar 13	11879046
Na+/Ca2+ exchanger in Na+ efflux-Ca2+ influx mode of operation exerts a neuroprotective role in cellular models of in vitro anoxia and in vivo cerebral ischemia.	2002 Nov	12502588
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.	2002 Nov	12419934
Na(+)/Ca(2+) exchanger in porcine oocytes.	2002 Oct	12297528
Transepithelial transport of bepridil in the human intestinal cell line, Caco-2, using a "dynamic model".	2003 Apr-Jun	12877575
Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm.	2003 Aug 15	12914884
Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect.	2003 Jan	12687836
Sodium-calcium exchange influences the response to endothelin-1 in lens epithelium.	2003 Sep	12887970

Patents

Sample Use Guides

In Vivo Use Guide

Initial dose: 200 mg once a day. Maintenance dose: 300-400 mg once a day.

Route of Administration: Oral

In Vitro Use Guide

In APP-overexpressing HEK293 cells lower Ab38, Ab40 and Ab42 generation was detected after Bepridil treatment (30 uM) for 16 h.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:53:44 GMT 2025` Edited by `admin` on `Mon Mar 31 17:53:44 GMT 2025`
Record UNII	4W2P15D93M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BEPRIDIL HYDROCHLORIDE MONOHYDRATE

Preferred Name

English

BEPRIDIL HYDROCHLORIDE

Official Name

English

Bepridil hydrochloride monohydrate [WHO-DD]

Common Name

English

1-PYRROLIDENEETHANAMINE, .BETA.-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-, MONOHYDROCHLORIDE, MONOHYDRATE

Common Name

English

BEPRIDIL HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

CERM 1978

Code

English

BEPADIN

Brand Name

English

NSC-758390

Code

English

UNICORDIUM

Brand Name

English

1-[2-(N-Benzylanilino)-1-(isobutoxymethyl)ethyl]-pyrrolidine monohydrochloride monohydrate

Systematic Name

English

BEPRIDIL HYDROCHLORIDE [MART.]

Common Name

English

BEPRIDIL HYDROCHLORIDE [VANDF]

Common Name

English

CORDIUM

Brand Name

English

BEPRIDIL HYDROCHLORIDE HYDRATE

Common Name

English

BEPRIDIL HYDROCHLORIDE HYDRATE [JAN]

Common Name

English

BEPRIDIL HYDROCHLORIDE MONOHYDRATE [MI]

Common Name

English

CERM-1978

Code

English

VASCOR

Brand Name

English

BEPRIDIL HYDROCHLORIDE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C333